A Four-Year Nationwide Study.
The TELESAT-HF (NCT06312501) is a national multicenter cohort study conducted in France between August 1, 2018, and December 31, 2022. It is based on data from more than 300 hospital and outpatient care centers, reflecting uniquely diverse clinical settings.
A total of 18,882 patients with heart failure were divided into two groups:
- Exposed group (RMP): 5,357 patients followed with the Satelia® Cardio program, based on symptom and weight monitoring without a connected scale, incorporating an alert algorithm and personalized therapeutic support.
- Unexposed group (SoC): 13,525 patients receiving standard care, identified through the French National Health Data System (SNDS).
The patients, whose average age was 72, had diverse clinical profiles: 56% had ischemic heart failure, 86% had hypertension, and 31% had diabetes.
Significant and Robust Results.
Patients followed with Satelia® Cardio saw a 36% reduction in all-cause mortality risk (HR = 0.64; 95% CI 0.59–0.70; p < 0.0001). These highly significant results were confirmed regardless of sex, age, disease severity, or patients’ digital literacy. This is the largest remote patient monitoring cohort studied to date in France and worldwide, demonstrating the clinical effectiveness of personalized follow-up based on an innovative algorithm that is simple to deploy and easy to use. These benefits demonstrate the overall impact of remote patient monitoring on care pathways and patients’ quality of life.
Figure 3 extracted from the publication. Kaplan–Meier survival curves of patients in the remote monitoring program (RMP) group versus the standard of care (SoC) group, overall (A) and according to heart failure (HF) hospitalizations and long-term illness (LTI) status (B–E). Hazard ratio (HR) in the overall population corresponds to weighted HR; HRs in the subgroups are derived from models adjusted for sociodemographic factors (age, sex, and deprivation index) and clinical characteristics (comorbidities and severity of HF).
A Major Step Forward for Remote Patient Monitoring.
The TELESAT-HF study highlights the impact of an accessible and ethical remote patient monitoring model. By focusing on symptom monitoring without relying on connected devices, and through tailored therapeutic support, Satelia® Cardio provides substantial added value compared with standard care. These results confirm that remote patient monitoring is an essential pillar in the management of chronic diseases and opens the way to broader adoption, both in France and internationally, for the benefit of patients.
Click here to download the study PDF
